Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | THPO | P40225 | 1/20 | 0.31 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.31 |
| ▸ | LCK | P06239 | 1/20 | 0.31 |
| ▸ | FYN | P06241 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6319 | 0.96 | ALDH1A1 (0.44) | ALDH1A1TSHRLMNAHSD17B10TDP1 | |
| SCHEMBL28578939 | 0.93 | ALDH1A1 (0.41) | ALDH1A1TSHRLMNAHSD17B10TDP1 | |
| SCHEMBL269725 | 0.93 | ALDH1A1 (0.41) | ALDH1A1TSHRLMNAHSD17B10TDP1 | |
| SCHEMBL1528 | 0.93 | ALDH1A1 (0.41) | ALDH1A1TSHRLMNAHSD17B10TDP1 | |
| SCHEMBL19518538 | 0.93 | ALDH1A1 (0.41) | ALDH1A1TSHRLMNAHSD17B10TDP1 | |
| SCHEMBL31146798 | 0.93 | ALDH1A1 (0.41) | ALDH1A1TSHRLMNAHSD17B10TDP1 | |
| Ammonia Solution, Strong SCHEMBL18860444 | 0.93 | ALDH1A1 (0.41) | ALDH1A1TSHRLMNAHSD17B10TDP1 | |
| SCHEMBL23121571 | 0.90 | ALDH1A1 (0.39) | ALDH1A1TSHRLMNAHSD17B10TDP1 | |
| SCHEMBL22472309 | 0.90 | ALDH1A1 (0.39) | ALDH1A1TSHRLMNAHSD17B10TDP1 | |
| Hydrochloric Acid SCHEMBL2000729 | 0.90 | ALDH1A1 (0.39) | ALDH1A1TSHRLMNAHSD17B10TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115677465-B | Preparation method of beta-cyclic citral | 新发药业有限公司 | 2024-09-10 | — | — | CN | claimed |
| CN-116660454-A | Method for detecting triacetoxyborohydride content | 四川青木制药有限公司 | 2023-08-29 | — | — | CN | claimed |
| EP-3766869-B1 | SIMPLE PREPARATION METHOD FOR AVIBACTAM | XINFA PHARMACEUTICAL CO LTD (CN) | 2023-05-10 | — | — | EP | claimed |
| CN-116063186-A | Process and intermediates for the preparation of (S) -2-amino-5, 7-difluoro-1, 2,3, 4-tetrahydronaphthalene hydrogen halides | 江苏亚虹医药科技股份有限公司 | 2023-05-05 | — | — | CN | claimed |
| CN-115677465-A | Preparation method of beta-cyclocitral | 新发药业有限公司 | 2023-02-03 | — | — | CN | claimed |
| CN-110734424-B | Preparation method of vonoprazan fumarate | 四川弘远药业有限公司 | 2022-12-13 | — | — | CN | claimed |
| CN-115232113-A | Process for the preparation of 5R- (((tetrahydro-2H-pyran-2-yl) oxy) amino) piperidine-2S-carboxylic acid ester salts | 山东致泰医药技术有限公司 | 2022-10-25 | — | — | CN | claimed |
| CN-113429380-B | Preparation method of duloxetine | 新发药业有限公司 | 2022-07-01 | — | — | CN | claimed |
| EP-3733648-B1 | METHOD FOR PREPARING 5R-BENZYLOXYAMINOPIPERIDIN-2S-CARBOXYLIC ACID OR DERIVATIVE THEREOF | XINFA PHARMACEUTICAL CO LTD (CN) | 2022-06-08 | — | — | EP | claimed |
| US-11208417-B2 | Simple process for preparing avibactam | XINFA PHARMACEUTICAL CO., LTD (CN) | 2021-12-28 | — | — | US | claimed |
| CN-110734424-A | preparation method of vonoprazan fumarate | 成都弘达药业有限公司 | 2020-01-31 | — | — | CN | claimed |
| EP-3546451-A1 | IMPROVED METHOD FOR PREPARATION OF 5R | Xinfa Pharmaceutical Co., Ltd (CN) | 2019-10-02 | — | — | EP | claimed |
| US-20190256514-A1 | Process for Preparing 5R-[(benzyloxy) amino] piperidine-2S-carboxylate and Oxalates Thereof | XINFA PHARMACEUTICAL CO., LTD (CN) | 2019-08-22 | — | — | US | claimed |
| US-20160168138-A1 | PROCESS FOR THE PREPARATION OF SUVOREXANT AND INTERMEDIATES USEFUL IN THE SYNTHESIS OF SUVOREXANT | REDDY S LAB LIMTED DR (IN) | 2016-06-16 | — | — | US | claimed |
| EP-3021851-A2 | PROCESS FOR THE PREPARATION OF SUVOREXANT AND INTERMEDIATES USEFUL IN THE SYNTHESIS OF SUVOREXANT | Dr. Reddy's Laboratories Ltd. (IN) | 2016-05-25 | — | — | EP | claimed |
| US-8183376-B2 | Stereoselective reduction of a morphinone | NEKTAR THERAPEUTICS (US) | 2012-05-22 | — | — | US | claimed |
| US-7374690-B2 | Processes for removing oil from solid wellbore materials and produced water | HALLIBURTON ENERGY SERVICES, INC. (US) | 2008-05-20 | — | — | US | claimed |
| US-20070125714-A1 | PROCESSES FOR REMOVING OIL FROM SOLID WELLBORE MATERIALS AND PRODUCED WATER | HALLIBURTON ENERGY SERVICES, INC. (US) | 2007-06-07 | — | — | US | claimed |
| US-7192527-B2 | Processes for removing oil from solid wellbore materials and produced water | HALLIBURTON ENERGY SERVICES, INC. (US) | 2007-03-20 | — | — | US | claimed |
| US-20060032820-A1 | Processes for removing oil from solid wellbore materials and produced water | HALLIBURTON ENERGY SERVICES, INC. | 2006-02-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11208417-B2 | Simple process for preparing avibactam | PGLS, CPS1, BPGM | ALDH1A1 1829/4885TSHR 2530/4885LMNA 4534/4885 |
| US-20190256514-A1 | Process for Preparing 5R-[(benzyloxy) amino] piperidine-2S-carboxylate and Oxalates Thereof | OTC, CA1, GLUL | ALDH1A1 328/4885TSHR 3935/4885LMNA 3102/4885 |
| US-20160168138-A1 | PROCESS FOR THE PREPARATION OF SUVOREXANT AND INTERMEDIATES USEFUL IN THE SYNTHESIS OF SUVOREXANT | KMO, HCRTR2, COMT | ALDH1A1 1864/4885TSHR 1303/4885LMNA 2754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.